A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma

NCT01551628 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped slow patient recruitment

Conditions

Leukemia
Lymphoma

Interventions

DRUG: Recombinant human arginase 1 Peg5000

Sponsor

Bio-Cancer Treatment International Limited

Collaborators

[object Object]